Acute Coronary Syndrome - Drug Pipeline Landscape, 2023
Description
Acute Coronary Syndrome - Drug Pipeline Landscape, 2023
Acute coronary syndrome is a term for a group of conditions that suddenly stop or severely reduce blood from flowing to the heart muscle. When blood cannot flow to the heart muscle, the heart muscle can become damaged. Acute coronary syndrome causes no cell death, the reduced blood flow changes how the heart works and is a sign of a high risk of heart attack.
Acute coronary syndrome usually results from the buildup of fatty deposits (plaques) in and on the walls of coronary arteries, the blood vessels delivering oxygen and nutrients to heart muscles. Plaque can tear suddenly, and a blood clot forms around it, severely narrowing or blocking the artery.
Signs and symptoms of acute coronary syndrome includes chest pain (angina) or discomfort, shortness of breath, sudden, heavy sweating, Feeling restless or apprehensive, fast, or irregular heartbeat.
Doctors most often diagnose acute coronary syndrome by using tests like electrocardiogram (ECG), A troponin blood test can show if the cells in the heart have been damaged, echocardiogram, coronary angiography, exercise stress test, nuclear stress test, stress echocardiography.
The most common investigative treatments include aspirin, beta blockers, statins, blood thinners, clot dissolving drugs, angiotensin converting enzyme (ACE) inhibitors, or nitroglycerin. Surgeries like angioplasty, bypass surgery to route the blood around the artery that is blocked, may improve outcomes.
Report Highlights
Global Insight Service’s, Acute Coronary Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Acute Coronary Syndrome pipeline drugs. This report covers detailed insights on Acute Coronary Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acute Coronary Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Acute coronary syndrome is a term for a group of conditions that suddenly stop or severely reduce blood from flowing to the heart muscle. When blood cannot flow to the heart muscle, the heart muscle can become damaged. Acute coronary syndrome causes no cell death, the reduced blood flow changes how the heart works and is a sign of a high risk of heart attack.
Acute coronary syndrome usually results from the buildup of fatty deposits (plaques) in and on the walls of coronary arteries, the blood vessels delivering oxygen and nutrients to heart muscles. Plaque can tear suddenly, and a blood clot forms around it, severely narrowing or blocking the artery.
Signs and symptoms of acute coronary syndrome includes chest pain (angina) or discomfort, shortness of breath, sudden, heavy sweating, Feeling restless or apprehensive, fast, or irregular heartbeat.
Doctors most often diagnose acute coronary syndrome by using tests like electrocardiogram (ECG), A troponin blood test can show if the cells in the heart have been damaged, echocardiogram, coronary angiography, exercise stress test, nuclear stress test, stress echocardiography.
The most common investigative treatments include aspirin, beta blockers, statins, blood thinners, clot dissolving drugs, angiotensin converting enzyme (ACE) inhibitors, or nitroglycerin. Surgeries like angioplasty, bypass surgery to route the blood around the artery that is blocked, may improve outcomes.
Report Highlights
Global Insight Service’s, Acute Coronary Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Acute Coronary Syndrome pipeline drugs. This report covers detailed insights on Acute Coronary Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acute Coronary Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
70 Pages
- 1. Introduction
- 1.1 Acute Coronary Syndrome – Pipeline Drugs, 2023-Coverage
- 2. Disease Overview – Acute Coronary Syndrome
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Acute Coronary Syndrome – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Late Stage Drugs - Pre-Registration
- 5.1.1 BAT2094
- 5.2 Clinical Stage Drugs - Phase III
- 5.2.1 CSL112
- 5.2.2 Dalcetrapib
- 5.2.3 DLBS1033
- 5.2.4 Evolocumab
- 5.3 Clinical Stage Drugs - Phase II
- 5.3.1 MT1002
- 5.4 Clinical Stage Drugs - Phase I
- 5.4.1 AZD5718
- 5.4.2 Vicagrel
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Amgen
- 9.2 AstraZeneca
- 9.3 Bio-Thera Solutions Ltd
- 9.4 CSL Behring
- 9.5 DalCor Pharmaceuticals
- 9.6 Dexa Medica Group
- 9.7 Jiangsu vcare pharmaceutical technology Co LTD
- 9.8 Shaanxi Micot Technology Limited Company
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - CSL112/CSL Behring
- Table 2.2 Clinical Trial Details - Dalcetrapib/DalCor Pharmaceuticals
- Table 2.3 Clinical Trial Details - DLBS1033/Dexa Medica Group
- Table 2.4 Clinical Trial Details - Evolocumab/Amgen
- Table 2.5 Clinical Trial Details - MT1002/Shaanxi Micot Technology Limited Company
- Table 2.6 Clinical Trial Details - AZD5718/AstraZeneca
- Table 2.7 Clinical Trial Details - Vicagrel/Jiangsu vcare pharmaceutical technology Co LTD
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Acute Coronary Syndrome, 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Acute Coronary Syndrome, 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Acute Coronary Syndrome, 2023
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Acute Coronary Syndrome, 2023
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Acute Coronary Syndrome, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
